吉西他滨单药治疗老年晚期非小细胞肺癌的临床观察  

Clinical Observation of Gemcitabine Monotherapy in the Treatment of Elder Patients with Advanced Non-small Cell Lung Cancer

作　　者：方立萍[1] 吴紫权 乔京京[1] 赵金波[1] 

机构地区：[1]大连医科大学附属第二医院肿瘤内科,辽宁省大连市116023 [2]大连沙医生整形美容口腔专科医院

出　　处：《中华全科医学》2010年第5期562-562,611,共2页Chinese Journal of General Practice

摘　　要：目的观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。方法38例Ⅲ～Ⅳ期NSCLC患者均经病理组织学或细胞学检查确诊。治疗剂量国产吉西他滨(泽菲)1000mg/m2,静滴,第1,8天,每3～4周重复,2周期后CT评价疗效。结果38例患者均可评价,获得CR0例,PR10例,有效率26.3%(10/38)。中位疾病进展时间(TTP)为6.1个月,中位生存期6.9个月,1年生存率27.2%。主要的毒副反应为白细胞及血小板降低,均可耐受。结论吉西他滨单药治疗老年晚期NSCLC疗效确切,可明显改善患者生存质量,延长生存时间,副反应轻,顺应性好。Objective To evaluate the clinical effect and toxicity of gemcitabine monotherapy in the treatment of elder patients with advanced non-small cell lung cancer（NSCLC）.Methods 38 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study,The patients received GEM 1 000 mg/m^2 on d1,d8,intravenously every 3-4 weeks and were evaluated effect after 2 cycles.Results Complete remisson（CR） was not observed and PR in 10 cases,the total response rate was 26.3%.The main side effects were leucopenia and thrombocytopenia,but they were tolerable.Conclusion The regimen of gemcitabine was effect,safe and well-tolerable in the treatment of elder patients with advanced NSCLC.It can significantly improve the quality of life in patients with NSCLC,and prolong the survial time.

关 键 词：非小细胞肺癌 吉西他滨 老年 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]